Boston Scientific Reports Surge in Q4 Sales, Guides Strong 2025 Outlook

Boston Scientific reported strong financial results for the fourth quarter of 2024, with net sales reaching $4.56 billion, a 22.4% increase year-over-year that surpassed analyst expectations. The company achieved adjusted earnings per share (EPS) of $0.70, exceeding the consensus estimate of $0.66, while GAAP net income rose to $566 million. CEO Mike Mahoney highlighted 2024 as one of the best years in the company's history, driven by innovative products like the FARAPULSE Pulsed Field Ablation System and robust demand for cardiology devices, which saw a 29% increase in sales. Looking ahead, Boston Scientific forecasts first-quarter adjusted EPS between $0.66 and $0.68 and projects annual EPS for 2025 in the range of $2.80 to $2.87. The positive results reflect the company's strong market position and operational efficiency, as it continues to transform patient care across various medical sectors. Overall, the outlook remains optimistic with expected sales growth in the upcoming year.